Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies. Linear pharmacokinetics were observed following either intravenous or oral administration. Plasma clearance averaged 463 ml min-1. Renal clearance averaged 310 ml min-1, which exceeded the glomerular filtration rate. Renal excretion was the major route of elimination. Urinary recovery of unchanged drug following intravenous administration was about 67 per cent. Famotidine plasma half-life was approximately 2.6 h. Oral absorption was incomplete. The bioavailability averaged 43 per cent of the dose.
D000284:Administration, Oral; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004311:Double-Blind Method; D004341:Drug Evaluation; D015738:Famotidine; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011485:Protein Binding; D011897:Random Allocation; D013535:Suspensions; D013607:Tablets; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology
D006635:Histamine H2 Antagonists; D013535:Suspensions; D013607:Tablets; D013844:Thiazoles; D015738:Famotidine